The antigenicity of a Plasmodium vivax reticulocyte binding protein-1 (PvRBP1) recombinant fragment in humans and its immunogenicity and protection studies in Aotus monkeys

Jose Rojas Caraballo, Gabriela Delgado, Raul Rodriguez, Manuel A. Patarroyo

Research output: Contribution to journalResearch Articlepeer-review

14 Scopus citations

Abstract

Plasmodium vivax merozoites have been found to specifically invade immature red blood cells (reticulocytes) and this preference has been associated with two proteins named reticulocyte binding protein-1 and protein-2 (PvRBP1 and PvRBP2). Previous reticulocyte binding assays using 15-mer synthetic peptides spanning the entire PvRBP1 sequence have shown that 25 out of the 195 peptides synthesised (grouped into 4 different regions) displayed high affinity binding to reticulocytes. The PvRBP1 region III (amino acids 1998-2348), encompassing 9 of the previously described high-affinity reticulocyte binding peptides, was expressed as a recombinant protein in the present study. This protein has been shown to be antigenic in humans and it has also been able to induce good humoral and cellular immune responses in Aotus nancymaae monkeys. Despite its high immunogenicity, no protective efficacy was observed in the immunised animals. © 2006 Elsevier Ltd. All rights reserved.
Translated title of the contributionAntigenicidad de un fragmento recombinante de la proteína-1 de unión a reticulocitos de Plasmodium vivax (PvRBP1) en humanos y estudios de inmunogenicidad y protección en monos Aotus
Original languageEnglish (US)
Pages (from-to)3713-3721
Number of pages9
JournalVaccine
Volume25
Issue number18
DOIs
StatePublished - May 4 2007
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Immunology

Fingerprint

Dive into the research topics of 'The antigenicity of a Plasmodium vivax reticulocyte binding protein-1 (PvRBP1) recombinant fragment in humans and its immunogenicity and protection studies in Aotus monkeys'. Together they form a unique fingerprint.

Cite this